Heart failure: An update

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 4, 2013, Pages 430-432

  Braunwald, E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ACUTE HEART INFARCTION; ARTICLE; ARTIFICIAL HEART PACEMAKER; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; HEALTH CARE COST; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MORBIDITY; POPULATION RISK; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

AGE FACTORS; HEART FAILURE; HUMANS; RISK FACTORS; STROKE VOLUME;

EID: 84884492028     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.149     Document Type: Article

References (5)

1. Braunwald, E. Shattuck lecture-cardiovascular medicine at the turn of the millennium: triumphs, concerns and opportunities. N. Engl. J. Med. 337, 1360-1369 (1997). (Pubitemid 27467771)
2. Go, A.S. et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127, e6-e245 (2013).
3. Braunwald, E. Heart failure. J. Am. Coll. Cardiol. H.F. 1, 1-20 (2013).
4. Kajstura, J. et al. Myocyte turnover in the aging human heart. Circ. Res. 107, 1374-1386 (2010).
5. Lal, H., Kolaja, K.L. & Force, T. Cancer genetics and the cardiotoxicity of the therapeutics. J. Am. Coll. Cardiol. 61, 267-274 (2013).